<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wang YC</submitter><funding>NHLBI NIH HHS</funding><pagination>371-389</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10923103</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>134(4)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Heart failure with preserved ejection fraction (HFpEF) is a common but poorly understood form of heart failure, characterized by impaired diastolic function. It is highly heterogeneous with multiple comorbidities, including obesity and diabetes, making human studies difficult.&lt;h4>Methods&lt;/h4>Metabolomic analyses in a mouse model of HFpEF showed that levels of indole-3-propionic acid (IPA), a metabolite produced by gut bacteria from tryptophan, were reduced in the plasma and heart tissue of HFpEF mice as compared with controls. We then examined the role of IPA in mouse models of HFpEF as well as 2 human HFpEF cohorts.&lt;h4>Results&lt;/h4>The protective role and therapeutic effects of IPA were confirmed in mouse models of HFpEF using IPA dietary supplementation. IPA attenuated </pubmed_abstract><journal>Circulation research</journal><pubmed_title>Indole-3-Propionic Acid Protects Against Heart Failure With Preserved Ejection Fraction.</pubmed_title><pmcid>PMC10923103</pmcid><funding_grant_id>R01 HL133169</funding_grant_id><funding_grant_id>R01 HL148577</funding_grant_id><funding_grant_id>R01 HL167831</funding_grant_id><funding_grant_id>R01 HL144651</funding_grant_id><funding_grant_id>R01 HL148110</funding_grant_id><funding_grant_id>P01 HL147823</funding_grant_id><pubmed_authors>Li XS</pubmed_authors><pubmed_authors>Koay YC</pubmed_authors><pubmed_authors>Wang YC</pubmed_authors><pubmed_authors>Rey FE</pubmed_authors><pubmed_authors>Hazen SL</pubmed_authors><pubmed_authors>Zhou Z</pubmed_authors><pubmed_authors>O'Sullivan JF</pubmed_authors><pubmed_authors>Pan C</pubmed_authors><pubmed_authors>Marques F</pubmed_authors><pubmed_authors>Kaye DM</pubmed_authors><pubmed_authors>Cao Y</pubmed_authors><pubmed_authors>Zagouras A</pubmed_authors><pubmed_authors>Lusis AJ</pubmed_authors><pubmed_authors>Wilcox J</pubmed_authors><pubmed_authors>Tang W</pubmed_authors><pubmed_authors>Allayee H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Indole-3-Propionic Acid Protects Against Heart Failure With Preserved Ejection Fraction.</name><description>&lt;h4>Background&lt;/h4>Heart failure with preserved ejection fraction (HFpEF) is a common but poorly understood form of heart failure, characterized by impaired diastolic function. It is highly heterogeneous with multiple comorbidities, including obesity and diabetes, making human studies difficult.&lt;h4>Methods&lt;/h4>Metabolomic analyses in a mouse model of HFpEF showed that levels of indole-3-propionic acid (IPA), a metabolite produced by gut bacteria from tryptophan, were reduced in the plasma and heart tissue of HFpEF mice as compared with controls. We then examined the role of IPA in mouse models of HFpEF as well as 2 human HFpEF cohorts.&lt;h4>Results&lt;/h4>The protective role and therapeutic effects of IPA were confirmed in mouse models of HFpEF using IPA dietary supplementation. IPA attenuated </description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Feb</publication><modification>2026-06-01T20:08:28.333Z</modification><creation>2025-04-07T07:50:15.236Z</creation></dates><accession>S-EPMC10923103</accession><cross_references><pubmed>38264909</pubmed><doi>10.1161/circresaha.123.322381</doi><doi>10.1161/CIRCRESAHA.123.322381</doi></cross_references></HashMap>